Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2018 Earnings Conference Call Transcript
Nov 07, 2018 • 04:30 pm ET
Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2018 Financial Results and Corporate Highlights Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
At this time, I'd like to turn it over to Matt Osborne, Voyager's Vice President of Corporate Affairs, Communications and Investor Relations. Please proceed.
Thank you. Good afternoon, and welcome to the conference call. This afternoon, we issued a press release which outlines the recent corporate highlights and financial results for the third quarter of 2018 and provides financial guidance for 2018. We also issued a separate press release providing an update on the longer-term clinical results with VY-AADC for Parkinson's disease. These releases are available at voyagertherapeutics.com.
Today on call, Andre Turenne, Voyager's President and CEO, will review our recent corporate and clinical program highlights; Dinah Sah, Voyager's Chief Scientific Officer, will review updates with our preclinical pipeline program; and Allison Dorval, Voyager's Chief Financial Officer, will review the financials. And then we will open up the call for your questions.
(Forward-Looking Cautionary Statements)
With that, I'll pass the call over to Andre.
Thank you, Matt, and good afternoon, everyone. Thank you for joining us on the call. As we highlighted in today's press releases, the third quarter was a productive one for the company with positive new data on both our lead program, VY-AADC for Parkinson's disease, and on our pipeline programs.
We described today in a separate press release the positive longer-term results from the ongoing open-label, dose-escalating Phase 1b clinical trial of VY-AADC. At the latest time point measured for each of the five patient cohorts, patients in the two highest dose cohorts experienced mean durable improvements in good ON time, which is ON time without troublesome dyskinesia, of 1.7 hours per day at 18 months for Cohort 3 and 2.7 hours per day at two years for Cohort 2.
Importantly, these improvements in good ON time were achieved with large and sustained reduction in daily oral levodopa and related medications in these two highest dose cohorts. This include a 43% reduction from baseline for Cohort 3 at 18 months and a 21% reduction from baseline for Cohort 2 at two years.
Since we've selected a dose of up to 2.5E12 vector genomes for the Phase 2, which is between the doses used in Cohorts 2 and 3 of the Phase 1b, combining the data from the 10 patients in these 2 cohorts provides the most relevant dataset. For this combined group of 10 patients, VY-AADC improved patients' good ON time by 2.4 hours per day at 12 months, which is the time point for the primary endpoint of the Phase 2 trial, and 2.6 hours per day at 18 months, which is the latest time point measured for both cohorts.
We've learned from the Phase 1b that patients with severe dyskinesia baseline could be more challenging to treat as they may take longer to settle in with good ON time after administration of